| A pragmatic–explanatory continuum indicator summary (PRECIS): a tool to help trial designers KE Thorpe, M Zwarenstein, AD Oxman, S Treweek, CD Furberg, ... Journal of clinical epidemiology 62 (5), 464-475, 2009 | 1637 | 2009 |
| Evidence for overuse of medical services around the world S Brownlee, K Chalkidou, J Doust, AG Elshaug, P Glasziou, I Heath, ... The Lancet 390 (10090), 156-168, 2017 | 961 | 2017 |
| NCD Countdown 2030: worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4 JE Bennett, GA Stevens, CD Mathers, R Bonita, J Rehm, ME Kruk, ... The lancet 392 (10152), 1072-1088, 2018 | 952 | 2018 |
| Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer K Halkidou, L Gaughan, S Cook, HY Leung, DE Neal, CN Robson The Prostate 59 (2), 177-189, 2004 | 711 | 2004 |
| How to formulate research recommendations P Brown, K Brunnhuber, K Chalkidou, I Chalmers, M Clarke, M Fenton, ... Bmj 333 (7572), 804-806, 2006 | 328 | 2006 |
| NCD Countdown 2030: pathways to achieving Sustainable Development Goal target 3.4 JE Bennett, V Kontis, CD Mathers, M Guillot, J Rehm, K Chalkidou, ... The Lancet 396 (10255), 918-934, 2020 | 312 | 2020 |
| Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development K Halkidou, VJ Gnanapragasam, PB Mehta, IR Logan, ME Brady, S Cook, ... Oncogene 22 (16), 2466-2477, 2003 | 278 | 2003 |
| Comparative effectiveness research and evidence‐based health policy: experience from four countries K Chalkidou, S Tunis, R Lopert, L Rochaix, PT Sawicki, M Nasser, B Xerri The Milbank Quarterly 87 (2), 339-367, 2009 | 200 | 2009 |
| Evidence-informed frameworks for cost-effective cancer care and prevention in low, middle, and high-income countries K Chalkidou, P Marquez, PK Dhillon, Y Teerawattananon, ... The lancet oncology 15 (3), e119-e131, 2014 | 183 | 2014 |
| Priority-setting for achieving universal health coverage K Chalkidou, A Glassman, R Marten, J Vega, Y Teerawattananon, ... Bulletin of the World Health Organization 94 (6), 462, 2016 | 174 | 2016 |
| The role for pragmatic randomized controlled trials (pRCTs) in comparative effectiveness research K Chalkidou, S Tunis, D Whicher, R Fowler, M Zwarenstein Clinical trials 9 (4), 436-446, 2012 | 171 | 2012 |
| Protocol for the development of guidance for stakeholder engagement in health and healthcare guideline development and implementation J Petkovic, A Riddle, EA Akl, J Khabsa, L Lytvyn, P Atwere, P Campbell, ... Systematic reviews 9, 1-11, 2020 | 150 | 2020 |
| Priority-setting in health: building institutions for smarter public spending A Glassman, K Chalkidou Washington, DC: Center for Global Development, 2012 | 138 | 2012 |
| Searching for cost effectiveness thresholds in the NHS J Appleby, N Devlin, D Parkin, M Buxton, K Chalkidou Health policy 91 (3), 239-245, 2009 | 138 | 2009 |
| Priority-setting institutions in health: recommendations from a center for global development working group A Glassman, K Chalkidou, U Giedion, Y Teerawattananon, S Tunis, ... Global heart 7 (1), 13-34, 2012 | 113 | 2012 |
| NCD Countdown 2030: efficient pathways and strategic investments to accelerate progress towards the Sustainable Development Goal target 3.4 in low-income and middle-income … NCD Countdown Lancet (London, England) 399 (10331), 1266, 2022 | 103 | 2022 |
| Evidence-based decision making: when should we wait for more information? K Chalkidou, J Lord, A Fischer, P Littlejohns Health Affairs 27 (6), 1642-1653, 2008 | 102 | 2008 |
| An introduction to the main types of economic evaluations used for informing priority setting and resource allocation in healthcare: key features, uses, and limitations HC Turner, RA Archer, LE Downey, W Isaranuwatchai, K Chalkidou, M Jit, ... Frontiers in public health 9, 722927, 2021 | 92 | 2021 |
| Reference case guidelines for benefit-cost analysis in global health and development LA Robinson, JK Hammitt, M Cecchini, K Chalkidou, K Claxton, ... | 87 | 2019 |
| Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate K Halkidou, S Cook, HY Leung, DE Neal, CN Robson European urology 45 (3), 382-389, 2004 | 82 | 2004 |
Anthony J CulyerUniversity of York在 york.ac.uk 的电子邮件经过验证
